Studies Currently Enrolling
Clinical trials are key to advancing the health care landscape and how we treat illnesses. Banner Alzheimer’s Institute (BAI) is proud to offer research studies to patients and people in the community. Studies here are focused on Alzheimer’s disease and other dementias. There are ways you can help research whether you have memory loss or not.
ClinicalTrials.gov identifier: n/a
Ages Eligible for Study: 47-68 years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: Yes
This study is sponsored by the National Institutes of Health (NIH) and is a long-term study that seeks to better understand the course of Alzheimer’s disease before clinical symptoms emerge. This brain imaging study, a collaboration with Mayo Clinic, will follow individuals indefinitely. The purpose is to observe the course of aging in participants with different genetic risk levels of developing different memory problems. The study includes visits every two years. Imaging visits include MRIs and PET scans. The study also includes optional lumbar punctures. Participants do not require a study partner.
Ages Eligible for Study: 47-68 years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: Yes
This study is sponsored by the National Institutes of Health (NIH) and is a long-term study that seeks to better understand the course of Alzheimer’s disease before clinical symptoms emerge. This brain imaging study, a collaboration with Mayo Clinic, will follow individuals indefinitely. The purpose is to observe the course of aging in participants with different genetic risk levels of developing different memory problems. The study includes visits every two years. Imaging visits include MRIs and PET scans. The study also includes optional lumbar punctures. Participants do not require a study partner.
GeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) Genotype (NCT02564692)
Alzheimer’s Disease Core Center (ADCC) (NCT01421420)
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol (NCT02854033)
Learn more: ADNI 3
GAIN Trial: Phase 2/3 Study of COR388 in Subjects with Alzheimer's Disease (NCT03823404)
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (NCT03443973)
Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease (Hope4MCI) (NCT03486938)